BioNexus Gene Lab Corporation has formally approved an Ethereum-focused treasury strategy Wednesday, becoming the first Nasdaq-listed company to exclusively prioritize Ethereum as a strategic asset.

The Wyoming-incorporated tech firm released its Ethereum Strategy Whitepaper alongside the announcement, detailing its rationale behind choosing Ethereum over the more commonly adopted Bitcoin for corporate treasury management.

"While Bitcoin remains a strong store of value, Ethereum provides broader utility as a programmable financial platform," the firm wrote on its Whitepaper, published Wednesday.

It was not immediately clear if the company has already purchased or holds Ethereum on its books. BioNexus has yet to respond to Decrypt's request for comment on that point.

BioNexus touts Ethereum's yield-generation capabilities through staking as a key advantage over Bitcoin, despite the latter’s adoption by institutional investors last year.

"Unlike Bitcoin, Ethereum provides an additional revenue stream through staking. Ethereum's Proof-of-Stake mechanism allows holders to generate 3-5% annual yield," the firm said in its Whitepaper, adding it could potentially turn Ethereum "from a passive asset into an income-generating treasury instrument."

BioNexus points to Ethereum's institutional credibility as another factor, noting Ethereum's adoption by major financial entities such as BlackRock and Fidelity validates "its long-term potential as a financial instrument."

The company also cites Ethereum's role in the global financial system, claiming the network "underpins trillions in stablecoin transactions annually, acting as the settlement layer for USDT, USDC, and other stablecoins."

BioNexus’ Ethereum Strategy Whitepaper specifically references the upcoming Pectra protocol upgrade, which it sees as something that could reinforce Ethereum's stature "as a dependable long-term infrastructure for businesses."

Despite the optimism, Pectra’s update has faced issues in recent weeks including during its Sepolia test network run early Wednesday, following similar roadblocks from its earlier Holesky testing phase.

BioNexus operates primarily in Asia through its Malaysian subsidiary, working in genomic diagnostics and chemical distribution.

Its provision of industrial chemical supplies for the automotive and aerospace sectors accounts for 90% of its total revenue. It has also developed RNA-based blood tests for early detection of cancers and inflammatory diseases, a segment that represents 10% of its revenue.

But for all its prospects with Ethereum, BioNexus appears to be battling financial challenges of its own.

In December last year, the company received a Nasdaq notice for non-compliance with the minimum $1 bid price rule.



A temporary exception was granted, giving it until May 1, 2025, to regain compliance. To address this, BioNexus plans a reverse stock split by April 7, 2025.

The company reported $9.26 million in trailing twelve-month revenue, over a $5.88 million market cap, with its stock trading at $0.32, down 61% on the year, data from the Financial Times shows.

Edited by Sebastian Sinclair

免责声明：本文章仅代表作者个人观点，不代表本平台的立场和观点。本文章仅供信息分享，不构成对任何人的任何投资建议。用户与作者之间的任何争议，与本平台无关。如网页中刊载的文章或图片涉及侵权，请提供相关的权利证明和身份证明发送邮件到support@aicoin.com，本平台相关工作人员将会进行核查。